Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 6:50 PM ET

Pharmaceuticals

Company Overview of Intersect ENT, Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

239 Employees

Phone:

650-641-2100

Key Executives for Intersect ENT, Inc.

Chief Executive Officer, President and Director
Age: 45
Total Annual Compensation: $332.4K
Chief Financial Officer and Principal Accounting Officer
Age: 57
Total Annual Compensation: $202.8K
Chief Operating Officer and Senior Vice President
Age: 53
Total Annual Compensation: $290.2K
Vice President of Sales
Age: 45
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2014.

Intersect ENT, Inc. Key Developments

Intersect ENT, Inc. Enrolls First Patient in Pivotal Study to Evaluate the Nova Sinus Implant

Intersect ENT, Inc. announced the enrollment of the first patient in the company's pivotal study of its latest bioabsorbable steroid releasing sinus implant, currently called NOVA. NOVA is designed to mechanically prop sinuses open while delivering anti-inflammatory medication following surgical interventions such as sinus surgery in the operating room or in-office sinus dilation. NOVA's unique hourglass shape and lower profile is designed to allow for placement in the smaller frontal and maxillary sinus openings, and may expand the applicable patient population for steroid releasing implants. The NOVA study is a prospective, randomized, blinded, multi-center trial of 80 patients designed to assess implant safety and efficacy. The company is conducting the NOVA trial as a second cohort of patients of the PROGRESS study. The first cohort of the PROGRESS study was an 80-patient prospective, randomized blinded multi-center trial to assess the safety and efficacy of the PROPEL® mini drug eluting implant to improve outcomes following frontal sinus surgery and was designed to support an expanded indication for PROPEL mini, currently approved for use in the ethmoid sinus. In addition to announcing the initiation of patient enrollment in the NOVA study, the company also announced that enrollment in the PROPEL mini cohort of the study has recently been completed.

Intersect ENT, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 09:30 AM

Intersect ENT, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 09:30 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Jeryl L. Hilleman, Chief Financial Officer and Principal Accounting Officer, Lisa D. Earnhardt, Chief Executive Officer, President and Director.

Intersect ENT, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 11:30 AM

Intersect ENT, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 11:30 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.

Similar Private Companies By Industry

Company Name Region
Perlan Therapeutics, Inc. United States
Orphan Therapeutics Limited Liability Company United States
Sigma-Tau Pharmaceuticals, Inc. United States
Iroko Pharmaceuticals, LLC United States
Durvet, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intersect ENT, Inc., please visit www.intersectent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.